



I M P O R T A N T I N F O R M A T I O N

BR200229

JULY 16, 2002

To All Providers:

- The Indiana State Department of Health issued a statement that there is currently a shortage of Prevnar (90669) and it cannot distribute adequate supplies of the vaccine to providers. On July 3, 2002, EDS modified IndianaAIM to allow payment up to the Medicaid maximum fee for Prevnar (90669), until the shortage is over. This modification impacts claims with dates of service (DOS) on or after June 19, 2002. Providers can submit claim adjustments when private stock was used for DOS on or after June 19, 2002, and the provider was previously paid the \$8 administration fee. Future banner page articles will be issued with additional information about potential changes in Prevnar (90669).

As a reminder, providers who cannot obtain the diphtheria, tetanus, and pertussis (DTaP) vaccine through the Vaccines for Children program may continue to bill the Indiana Health Coverage Programs (IHCP) their usual and customary charge for DTaP.

- EDS announces the addition of a question and answer session at the IHCP 2002 Seminar, scheduled for August 6 through 8, 2002. These sessions will be held each day from 4 p.m. to 5 p.m., in classroom A, and preregistration is not required. In these sessions, providers may ask questions about Medicaid Select, Disease Management/Case Management, and Pharmacy Benefit Manager. These sessions are in development, and future banner page articles will be issued as information becomes available.
- EDS and the Office of Medicaid Policy and Planning (OMPP) are in the process of distributing bulletin, *BT200226* to all IHCP providers. This bulletin announces the upcoming IHCP 2002 Seminar that will be held August 6, through 8, 2002, at the Mount Pleasant Christian Church Community Center located in Greenwood, Indiana. Enclosed with this banner page is a copy of the seminar registration form. Immediate access to the class schedule and registration form is available at www.indianamedicaid.com Web site. EDS and the OMPP extended the deadline for reservations to **July 31, 2002**.
- Information about the *IHCP 2002 Seminar* appears in bulletin, *BT200226*. This provides additional information about the Waiver Review Session being presented during the seminar. The OMPP established a review process for the Home and Community Based Services (HCBS) Waiver programs. The focus of the review process is to help HCBS Waiver providers achieve IHCP compliant documentation and billing, to help ensure the health and safety of IHCP members. This session provides an overview of the review process. The session is targeted to agencies providing the following waiver services to individuals on the Developmentally Disabled Waiver Program: personal assistance, residential based habilitation services, support services, behavior management, residential habilitation and support, and community habilitation and support.

In the second hour of the session the Bureau of Quality Improvement Service (BQIS) presents information about the *Bureau of Developmental Disabilities Services Incident Reports*. A question and answer period follows the BQIS presentation and providers are encouraged to bring for discussion any copies of forms being used to record services provided to waiver members.

To All Pharmacy Providers:

Note: The information referenced below is not directed to those providers rendering services in the risk-based managed care delivery system.

- The following changes to the Medicaid Drug Federal Upper Limit are effective August 1, 2002:

Deletions	
Generic Name	Dosage
Ampicillin/Ampicillin Trihydrate	250 mg, capsule, oral, 100 500 mg, capsule, oral, 100
Codeine Phosphate; Promethazine Hydrochloride	10 mg/5 ml; 6.25 mg/5 ml, syrup, oral, 480 ml
Desipramine Hydrochloride	10 mg, tablet, oral, 100 25 mg, tablet, oral, 100 50 mg, tablet, oral, 100 75 mg, tablet, oral, 100 100 mg, tablet, oral 100
Hydroxyurea	500 mg, capsule, oral, 100
Hydroxyzine Hydrochloride	10 mg, tablet, oral, 100 25 mg, tablet, oral, 100 50 mg, tablet, oral, 100
Methocarbamol	750 mg, tablet, oral, 100

The following rate changes are effective August 1, 2002:

Price Increases		
Generic Name	Dosage	New Price
Allopurinol	300 mg, tablet, oral, 100	\$0.1671
Amantadine Hydrochloride	100 mg, capsule, oral, 100	\$0.2463
Amitriptyline Hydrochloride	10 mg, tablet, oral, 100	\$0.0891
	25 mg, tablet, oral, 100	\$0.0936
Bumetanide	1 mg, tablet, oral, 100	\$0.2348
	2 mg, tablet, oral, 100	\$0.4272

CDT-3/2000 (including procedure codes, definitions (descriptions) and other data) is copyrighted by the American Dental Association. © 1999 American Dental Association. All rights reserved. Applicable Federal Acquisition Regulation System/Department of Defense Acquisition Regulation System (FARS/DFARS) Apply.

CPT codes, descriptions and other data only are copyright 1999 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Apply.